The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2024 | Overview and advances in tumor treatment fields (TTFields)
Ticiana Leal, MD, Winship Cancer Institute, Atlanta, GA, outlines what tumor treatment fields (TTFields) treatment entails and its potential advancements. TTFields are electric fields tuned to a frequency that interferes with mitosis, thereby disrupting the rapid cell division in cancers and tumors, as well as stimulating an enhanced immune response. TTFields has been approved for glioblastomas and malignant pleural mesotheliomas and its efficacy against non-small cell lung cancer (NSCLC) was assessed in the Phase III LUNAR study (NCT02973789), where patients received the standard of care (an immune checkpoint inhibitor or docetaxel) with or without TTFields. TTFields combined therapy demonstrated improved overall survival (OS), particularly in combination with immune checkpoint inhibitors. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
